Newspatrolling.com News cum Content Syndication Portal Online
- Total income for 9M FY24 stood at Rs.1,651 crore against Rs.1,647 crore YoY
- EBITDA for 9M FY24 at Rs.204.0 crore up by 38.4% YoY
- Net profit for 9M FY24 at Rs.107.2 crore up by 43.5% YoY
- Received CEP Certificate for Losartan Potassium issued by EDQM which will enable higher export to European market
- The Board declared an Interim Dividend of Rs.5/- Share
08th February, 2024, New Delhi:
IOL Chemicals and Pharmaceuticals Ltd, a leading manufacturer of pharmaceutical APIs and speciality chemicals, announced its financial results for the third quarter and nine months ended December 31, 2023.
Consolidated Q3 & 9M FY24 Financial Highlights
(Rs. in Crore)
| Particulars | Q3 FY24 | Q3 FY23 | % YoY | 9M FY24 | 9M FY23 | % YoY |
| Total Income | 528.8 | 530.1 | -0.2% | 1651.4 | 1,646.8 | 0.3% |
| EBITDA | 52.9 | 49.7 | 6.4% | 204.0 | 147.6 | 38.2% |
| EBITDA Margin (%) | 10.0% | 9.4% | 60 bps | 12.3% | 8.9% | 340 bps |
| PAT | 23.2 | 24.2 | -4.1% | 107.2 | 74.7 | 43.5% |
| PAT Margin (%) | 4.4% | 4.6% | -20 bps | 6.5% | 4.5% | 200 bps |
Commenting on the performance, Mr Vikas Gupta, Joint Managing Director said, “Despite sectoral headwinds, the Company has shown resilience in its financial performance during nine months period. The company’s EBITDA margin has improved led by declining input cost. We recently received CEP certificate approval for Losartan Potassium by EDQM providing us an opportunity to further expand our exports into the regulated markets. We are continuously focusing on improving operational efficiencies further through backward integration.”
